This activity is part of the Frankly Speaking with Dr. Frank Domino podcast series.
Tile overview image

Podcast

0.25 CME/CE Credit

Biennial Screening Could Decrease False Positives in Screening Mammography - Frankly Speaking EP 287Guest: Jill M. Terrien, PhD, ANP-BC
Music Credit: Richard Onorato

Join us to discuss the rates of false positives in mammography and how to decrease them. Specifically, this session reviews data from an observational comparative effectiveness study suggesting that the type of mammography, interval, and other factors can affect the probability of false positive results. 

Episode Resources and Links: 

  • Ho TH, Bissell MCS, Kerlikowske K, et al. Cumulative Probability of False-Positive Results After 10 Years of Screening With Digital Breast Tomosynthesis vs Digital Mammography. JAMA Netw Open. 2022;5(3):e222440. doi:10.1001/jamanetworkopen.2022.2440
  • Breast Cancer Screening Guidelines for Women (CDC Chart)—Last reviewed 9-2020 https://www.cdc.gov/cancer/breast/pdf/breast-cancer-screening-guidelines-508.pdf
  • Canelo-Aybar, C., Posso, M., Montero, N. et al. Benefits and harms of annual, biennial, or triennial breast cancer mammography screening for women at average risk of breast cancer: a systematic review for the European Commission Initiative on Breast Cancer (ECIBC). Br J Cancer 126, 673–688 (2022). https://doi.org/10.1038/s41416-021-01521-8
     

     

     

Begin

Already listened on another platform?

Claim Credits

CME/CE Information

0.25 AMA PRA Category 1 Credits

Release Date: 8/1/2022

Expiration Date: 8/1/2024

Learning Objectives

  • Describe factors that may decrease false positives in screening mammography
  • Appreciate the role shared decision-making should play in discussions on mammography screening 
     

     

Faculty

Frank J. Domino, MD

Professor, Family Medicine and Community Health,
University of Massachusetts Medical School, Worcester, MA

Learn More

Jill M. Terrien, PhD, ANP-BC

Associate Professor, Director NP Programs
UMMS-GSN 

Learn More

Disclosures

The following financial relationships have been disclosed by faculty.

Frank J. Domino, MD

Has disclosed no relevant financial relationships. 

Jill Terrien PhD, ANP-BC 

Has disclosed no relevant financial relationships. 

 

Non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationships to disclose.

CME/CE Information

AMA PRA Category 1 Credits

Accreditation Statement

Pri-Med Institute is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation Statement

Pri-Med Institute designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

For APRNs and PAs, AANPCB and NCCPA accept AMA PRA Category 1 Creditâ„¢ as the number of hours of participation (AANPCB) or as Category 1 CME credits (NCCPA).

Supporters and Partners

Commercial Supporter

Not Applicable

Education Partner

Not Applicable

Fine Print

The preferred browser is Google Chrome. If using a different browser, such as Safari, Firefox or Edge, make sure you are using the most up-to-date version. Your Internet settings should be set to accept cookies and JavaScript. If cookies and/or JavaScript are disabled, the site may not function properly. A high-speed Internet connection is not required; however, it is recommended for faster download times.

The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed by, nor do they necessarily reflect, those of their affiliated institutions, Pri-Med Institute, Pri-Med Institute Advisory Boards and Consultants, DBC Pri-Med, LLC.

Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients.

Pri-Med Institute educational activities are developed and conducted in accordance with the ACCME's Essential Areas and Policies. It is the mission of Pri-Med Institute to develop and present educational activities that are timely, fair-balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome your comments about how to better serve your needs.

Pri-Med Institute Accredited Provider
Pri-Med programs are owned and operated by DBC Pri-Med, LLC, a division of Diversified Communications, Inc. Pri-Med Institute, the accredited division of Pri-Med, is accredited with commendation by the ACCME and approved as a provider of continuing education by the AANP. Pri-Med Institute is the accredited provider for this activity.

Disclosures and Conflict of Interest
Pri-Med Institute requires all individuals in a position to influence educational content for Pri-Med Institute-certified CME/CE activities to disclose relevant personal financial relationships with commercial interests prior to contributing to its educational activities. Pri-Med Institute assesses disclosed relationships and follows a defined process to resolve real or implied conflicts to ensure, to the best of its ability, that all educational content is free of commercial bias. Financial disclosures are listed in the activity syllabus and will also be printed on the slides and announced at the start of each presentation.

Discussion of Off-Label Uses and Investigational Products
During the course of their presentations, the faculty may mention uses of products that have not been approved in the United States for the indication(s) being discussed. All presenters are instructed to notify participants when they are discussing unapproved uses or investigational agents. In addition, specific slides will include notation of the off-label use or investigational agent being discussed. Views presented related to unapproved uses of products are solely those of the presenter(s) and are not endorsed by Pri-Med Institute or DBC Pri-Med, LLC.

Questions? If you have questions about this activity, please email support@pri-med.com or call (877) 477-4633.

Biennial Screening Could Decrease False Positives in Screening Mammography - Frankly Speaking EP 287

Begin